Potent Personalized Venetoclax Partners for Acute Myeloid Leukemia Identified by Ex Vivo Drug Screening

被引：0

作者：

Becker, Pamela S. ^{[1
,2
,3
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Natl Med Ctr, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Duarte, CA 91010 USA

[3] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD CANCER DISCOVERY | 2023年 / 4卷 / 06期

关键词：

OLDER PATIENTS;

D O I：

10.1158/2643-3230.BCD-23-0180

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-throughput screens (HTS) have been utilized to assess the efficacy of single drugs against patient tumor samples with the purpose of optimizing precision therapy, but testing the synergy of drug combinations can identify the ideal second drug to add. With novel sophisticated HTS, effective venetoclax combinations can be revealed that provide the cell state, phenotype, and molecular features of the susceptible and resistant cell populations.

引用

页码：437 / 439

页数：3

共 50 条

[41] Personalized Therapy for Acute Myeloid Leukemia
Hourigan, Christopher S.
Karp, Judith E.
[J]. CANCER DISCOVERY, 2013, 3 (12) : 1336 - 1338
[42] Effective orally available drug combination of OR2100 and venetoclax in acute myeloid leukemia
Ureshino, Hiroshi
Watanabe, Tatsuro
Kimura, Shinya
[J]. CANCER SCIENCE, 2023, 114 : 44 - 44
[43] Prognostic impact of combined ex vivo drug resistance to fludarabine, treosulphan and mitoxantrone in childhood acute myeloid leukemia
Styczynski, J
Wysocki, M
Dluzniewska, A
Czyzewski, K
Debski, R
Kubicka, M
Rafinska, B
Kolodziej, B
Juraszewska, E
Balwierz, W
Olejnik, I
Wieczorek, M
Kuzmicz, M
Krawczuk-Rybak, M
Stefaniak, J
Kowalczyk, J
Badowska, W
Szczepanski, T
Jakimczyk, DS
Stanczak, E
Malinowska, I
Matysiak, M
Konatkowska, B
Wachowiak, J
Kapuscinska, L
Balcerska, A
[J]. BLOOD, 2005, 106 (11) : 780A - 780A
[44] Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
Cucchi, David G. J.
Bachas, Costa
van den Heuvel-Eibrink, Marry M.
Arentsen-Peters, Susan T. C. J. M.
Kwidama, Zinia J.
Schuurhuis, Gerrit J.
Assaraf, Yehuda G.
de Haas, Valerie
Kaspers, Gertjan J. L.
Cloos, Jacqueline
[J]. CANCERS, 2020, 12 (05)
[45] Venetoclax for every patient diagnosed with acute myeloid leukemia?
Cailly, Laura
Gallego-Hernanz, Maria-Pilar
Torregrosa-Diaz, Jose-Miguel
[J]. HEMATOLOGIE, 2022, 28 (01): : 6 - 8
[46] Venetoclax-based therapies for acute myeloid leukemia
Guerra, Veronica A.
DiNardo, Courtney
Konopleva, Marina
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 145 - 153
[47] Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
Rodriguez-Medina, Carlos
Stuckey, Ruth
Bilbao-Sieyro, Cristina
Gomez-Casares, Maria Teresa
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
[48] Outpatient initiation of venetoclax in patients with acute myeloid leukemia
Palmer, Shannon
Patel, Anand
Wang, Christopher
Patel, Bianka
Zeidner, Joshua
Foster, Matthew
Muluneh, Benyam
Buhlinger, Kaitlyn
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1590 - 1598
[49] Venetoclax-containing regimens in acute myeloid leukemia
Aldoss, Ibrahim
Pullarkat, Vinod
Stein, Anthony S.
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[50] Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia
Bouligny, Ian M.
Murray, Graeme
Ho, Thuy
Doyel, Michael
Patel, Tilak
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Alnimer, Yanal
Zacholski, Kyle
Venn, Chad
Wages, Nolan A.
Grant, Steven
Maher, Keri R.
[J]. LEUKEMIA RESEARCH, 2023, 134

← 1 2 3 4 5 →